Navigation Links
CEL-SCI CORPORATION Reports Third Quarter 2008 Financial Results
Date:8/20/2008

eir effectiveness.

The Company has operations in Vienna, Virginia and Baltimore, Maryland. CEL-SCI's other products, which are currently in pre-clinical stage, have shown protection against a number of diseases in animal tests and are being tested against diseases associated with bio-defense.

CEL-SCI CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(unaudited)

Three Months Ended

June 30,

2008 2007

REVENUE:

Grant revenue $ 3,535 $ -

Rent income - 5,734

Other income - 715

Total Revenue 3,535 6,449

EXPENSES:

Research and development, excluding

depreciation of $7,246 and $21,086

included below 975,183 632,868

Depreciation and amortization 27,743 45,089

General and administrative 1,177,288 3,104,755

Total Expenses 2,180,214 3,782,712

LOSS FROM OPERATIONS (2,176,679) (3,776,263)

GAIN (LOSS) ON DERIVATIVE INSTRUMENTS 206,106 (1,090,471)

INTEREST INCOME 94,333 190,112

INTEREST EXPENSE (113,038) (878,354)

NET LOSS BEFORE INCOME TAXES (1,989,278) (5,554,976)

INCOME TAX PROVISION - -

NET LOSS (1
'/>"/>

SOURCE CEL-SCI CORPORATION
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. CEL-SCI Announces Exclusive Licensing Agreement with Teva for Cancer Drug Multikine
2. CEL-SCI CORPORATION Manufacturing Facility for Pivotal Phase III Cancer Trial Scheduled to Be Completed During 2008 Third Quarter
3. CEL-SCI to Present at the Noble Financial Conference
4. Emerging Growth Equities, Ltd. Initiates Coverage of CombiMatrix Corporation with a BUY Rating and an $18.00 Price Target
5. [video] David Brown, President and CEO of LifeVantage Corporation, Discusses Record Page Views on WallSt.nets 3-Minute Press Show
6. MannKind Corporation Reports Second Quarter Financial Results
7. Genaera Corporation Announces Second Quarter Financial Results
8. China Bionanometer Industries Corporation Promotes New Product Beauty Look in China
9. Pharmos Corporation Reports 2008 Second Quarter Results
10. Verenium Corporation to Present at Canaccord Adams 28th Annual Global Growth Conference
11. Vista Partners Updates Coverage on Inovio Biomedical Corporation (Amex: INO); $3.57 Price Target
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)...  Xencor, Inc. (NASDAQ: XNCR ), ... for the treatment of autoimmune diseases, asthma and ... of Debra Zack , M.D., Ph.D., vice ... Lloyd Rowland , senior vice president, chief compliance ... expertise in biologics clinical development and medical affairs ...
(Date:9/2/2014)... Mount, NC (PRWEB) September 02, 2014 ... establishment of its 11th clinical research site: PMG Research ... assumed ownership and operation of the clinical research department ... further expanding PMG’s presence in eastern North Carolina. This ... patients. For the patients in Rocky Mount and the ...
(Date:9/1/2014)... 2014 Reportlinker.com announces that a new ... India Solid Waste Management Vehicles Market ... http://www.reportlinker.com/p02350445/India-Solid-Waste-Management-Vehicles-Market-Forecast-and-Opportunities-2019.html In India ... bodies responsible for complete handling and regulation of ... around 135,000 MT solid waste is generated daily ...
(Date:8/31/2014)... Available spectra is similar for all L-series ... of a wide range of plants. The spectra ... patented and pending wide spectrum technology. The single ... applications in contrast to growth spectra made from ... a large variety of differently sized and shaped ...
Breaking Biology Technology:Xencor Appoints Debra Zack, M.D., Ph.D., Vice President, Clinical Development and Lloyd Rowland, Senior Vice President, Chief Compliance Officer and General Counsel 2Xencor Appoints Debra Zack, M.D., Ph.D., Vice President, Clinical Development and Lloyd Rowland, Senior Vice President, Chief Compliance Officer and General Counsel 3PMG Research Announces the Formation of its Eleventh Site 2PMG Research Announces the Formation of its Eleventh Site 3India Solid Waste Management Vehicles Market Forecast and Opportunities, 2019 2India Solid Waste Management Vehicles Market Forecast and Opportunities, 2019 3India Solid Waste Management Vehicles Market Forecast and Opportunities, 2019 4India Solid Waste Management Vehicles Market Forecast and Opportunities, 2019 5India Solid Waste Management Vehicles Market Forecast and Opportunities, 2019 6India Solid Waste Management Vehicles Market Forecast and Opportunities, 2019 7India Solid Waste Management Vehicles Market Forecast and Opportunities, 2019 8
... Identify Potential Initiation Dosing Regimen , ... palmitate, an investigational long-acting therapy (LAT) demonstrated statistically significant ... of a 13-week study presented today (1). Statistical ... and 150 mg equivalent [eq.a]), when given every 4 ...
... the Journal Blood for the American Society of Hematology Annual ... Dec. 10 Alfacell Corporation (Nasdaq: ACEL ) ... abstracts in Blood (2008 112: Abstract 4205 & ... (R-Amph) show anti-tumor activity in chronic lymphocytic leukemia (CLL) and ...
... Calif., Dec. 10 Valeant,Pharmaceuticals International (NYSE: ... signed a,definitive agreement to acquire Dow Pharmaceutical Sciences, ... the development of topical,products on a proprietary basis, ... The transaction significantly enhances Valeant,s,dermatology franchise in the ...
Cached Biology Technology:Phase 3 Data Demonstrate Efficacy and Tolerability of Paliperidone Palmitate, an Investigational Long-Acting Therapy for the Treatment of Schizophrenia 2Phase 3 Data Demonstrate Efficacy and Tolerability of Paliperidone Palmitate, an Investigational Long-Acting Therapy for the Treatment of Schizophrenia 3Phase 3 Data Demonstrate Efficacy and Tolerability of Paliperidone Palmitate, an Investigational Long-Acting Therapy for the Treatment of Schizophrenia 4Phase 3 Data Demonstrate Efficacy and Tolerability of Paliperidone Palmitate, an Investigational Long-Acting Therapy for the Treatment of Schizophrenia 5Phase 3 Data Demonstrate Efficacy and Tolerability of Paliperidone Palmitate, an Investigational Long-Acting Therapy for the Treatment of Schizophrenia 6Phase 3 Data Demonstrate Efficacy and Tolerability of Paliperidone Palmitate, an Investigational Long-Acting Therapy for the Treatment of Schizophrenia 7Phase 3 Data Demonstrate Efficacy and Tolerability of Paliperidone Palmitate, an Investigational Long-Acting Therapy for the Treatment of Schizophrenia 8Phase 3 Data Demonstrate Efficacy and Tolerability of Paliperidone Palmitate, an Investigational Long-Acting Therapy for the Treatment of Schizophrenia 9Alfacell's ONCONASE(R) and R-Amphinase Show Anti-Tumor Activity in Chronic Lymphocytic Leukemia and Acute Myeloblastic Leukemia Cells 2Alfacell's ONCONASE(R) and R-Amphinase Show Anti-Tumor Activity in Chronic Lymphocytic Leukemia and Acute Myeloblastic Leukemia Cells 3Alfacell's ONCONASE(R) and R-Amphinase Show Anti-Tumor Activity in Chronic Lymphocytic Leukemia and Acute Myeloblastic Leukemia Cells 4Alfacell's ONCONASE(R) and R-Amphinase Show Anti-Tumor Activity in Chronic Lymphocytic Leukemia and Acute Myeloblastic Leukemia Cells 5Valeant to Acquire Dow Pharmaceutical Sciences, Inc. for $285 Million 2Valeant to Acquire Dow Pharmaceutical Sciences, Inc. for $285 Million 3Valeant to Acquire Dow Pharmaceutical Sciences, Inc. for $285 Million 4Valeant to Acquire Dow Pharmaceutical Sciences, Inc. for $285 Million 5
(Date:9/2/2014)... Passerine birds, also known as perching birds, that migrate ... they do in autumn to reach their destinations. This ... birds that only make short migratory flights, says researcher ... journal Behavioral Ecology and Sociobiology . , ... used a tracking radar to measure over three years ...
(Date:9/2/2014)... Air pollution regulations over the last decade in Taiyuan, ... there, accounting for a greater than 50% reduction in ... 2001 and 2010, according to researchers at the Columbia ... School of Public Health, the Shanxi Medical University, the ... and Shanghai Fudan University School of Public Health. , ...
(Date:9/2/2014)... stride; others are done in by it. New research ... this so-called stress gap in mice with very similar ... to better understand the development of psychiatric disorders such ... has unique experiences as it goes through its life. ... the expression of genes, and as a result, affect ...
Breaking Biology News(10 mins):Migrating birds sprint in spring, but take things easy in autumn 2Clean air halves health costs in Chinese city 2Discovery hints at why stress is more devastating for some 2Discovery hints at why stress is more devastating for some 3
... speech President Bush said technology is the best way to ... Energy Joint Genome Institute (DOE JGI) is directing the technology ... will lead to cheaper and easier to produce biofuels. ... molecular biology we can generate diagnostic fingerprints, Environmental Genomic Tags ...
... the March 24 Cell reports the discovery of a ... could offer a potential new target for countermeasures against ... therapies might have the potential to protect against anthrax ... have lost their therapeutic value, they added. , The ...
... Scientists have for many years debated the cause of ... Papagrigorakis and colleagues using DNA collected from teeth from ... as the disease responsible for this devastating epidemic. The ... Journal of Infectious Diseases (IJID) published by Elsevier on ...
Cached Biology News:Environmental metagenomics diagnosing extreme environments, tapping opportunities for clean energy 2Driver of anthrax toxicity could lead to late-stage therapy 2Typhoid fever led to the fall of Athens 2
... Reagents are complete ready-to-use reagents for the ... is specifically formulated for the isolation of ... is specifically formulated for the isolation of ... with DNAzol Reagents can be used for ...
Apoptosis Detection Systems and Reagents...
... rodent oral gavage feature soft rubber tips ... trauma. Plus they are disposable, to eliminate ... of cross-contamination. Diameter: ... Length: ...
DAPI: 4', 6-Diamino-2-phenylindole dihydrochloride. Antifade Solution: p-Phenylenediamine and glycerol in PBS solution. 0.4g/mL DAPI suspended in Antifade....
Biology Products: